Are IL-6 inhibitors one key to COVID-19? EUSA Pharma joins Sanofi, Regeneron in rolling out trials
EUSA's Sylvant is being tested to treat COVID-19 in an observational trial in Italy. (Getty)
Sanofi and Regeneron are putting their hopes in IL-6 inhibitor Kevzara as a possible therapy for COVID-19 with clinical trials underway. Now, a second IL-6 med rolling into trial in an Italian hospital, potentially showing promise for the class as a whole.
EUSA Pharma has launched an observational study of IL-6 med Sylvant (siltuximab) to treat patients with severe COVID-19 in Bergamo, Italy's Papa Giovanni XXIII Hospital, the British drugmaker said in a release Wednesday.
The study will evaluate Sylvant's ability to reduce the need for invasive ventilation, time spent in intensive care and 30-day mortality for patients prior to intensive care or those already admitted, EUSA said. Any of those clinical results could prove crucially important for an Italian healthcare system overrun with more than 31,000 COVID-19 cases as of Wednesday and more than 2,500 deaths, the highest toll in Europe.
Sponsored by Lubrizol Life Science
[Webinar] Cannabinoid Formulation - from Farm to Pharma
Wednesday, June 24, 2020 | 12pm ET / 9am PT
A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.
Sylvant, approved in the U.S. to treat patients with multicentric Castleman disease who are HIV and herpes negative, is the most recent IL-6 targeted for COVID-19 trials after the drugs showed promise in early clinical trials coming out of China.